|
Breast Cancer

- Breast Cancer - a
comprehensive overview
-
http://www.emedicine.com/med/topic2808.htm
- Breast Cancer - a
comprehensive overview -
http://en.wikipedia.org/wiki/Breast_cancer
- Breast Cancer - a
comprehensive overview -
http://info.cancerresearchuk.org/cancerandresearch/cancers/breast/
- NICE Guidelines: Improving outcomes in breast cancer - Manual update -
http://www.nice.org.uk/page.aspx?o=csgbcguidance
- NICE Guidelines: Improving Outcomes in breast cancer - Research evidence
-
http://www.nice.org.uk/page.aspx?o=36020
- American Society of Clinical Oncology (ASCO) Patient Guide:
Bisphosphonates for Breast Cancer -
http://www.plwc.org/plwc/MainConstructor/1,1744,_12-001129-00_14-00Patient%20Guides-00_17-001029-00_18-0031017-00_19-0031018-00_20-001-00_21-008,00.asp
- American Society of Clinical Oncology (ASCO) Patient Guide:
Understanding Tumour Markers for Breast and Colorectal Cancers -
http://www.plwc.org/plwc/MainConstructor/1,1744,_12-001129-00_14-00Patient%20Guides-00_17-001029-00_18-009317-00_19-0010006-00_20-001-00_21-008,00.asp
- American Society of Clinical Oncology (ASCO) Patient Guide: Preventing
and Treating Nausea and Vomiting Caused by Cancer Treatment -
http://www.plwc.org/plwc/MainConstructor/1,1744,_12-001129-00_14-00Patient%20Guides-00_17-001029-00_18-008042-00_19-0024556-00_20-001-00_21-008,00.asp
- American Society of Clinical Oncology (ASCO) Patient Guide: Follow-Up
Care for Breast Cancer -
http://www.plwc.org/plwc/MainConstructor/1,1744,_12-001129-00_14-00Patient%20Guides-00_17-001029-00_18-008028-00_19-008029-00_20-001-00_21-008,00.asp
Genetics of the Breast Cancer:
- Genes Implicated
in Hereditary Breast Cancer Syndromes:
The medical histories of breast cancer-prone families have been described for
over a century. The pattern of breast cancer occurrences in these families is
most consistent with an autosomal dominant mode of inheritance. The location of
a gene that could explain the pattern of transmission of the breast cancer trait
in families averaging early (pre-menopausal) onset of breast cancer was reported
in 1990. Since then, two genes have been identified: BRCA1 and BRCA2. Germ-line
mutations in these two genes confer susceptibility to breast (female and male)
and ovarian cancer, and account for a significant proportion of hereditary
breast cancer in two cancer syndromes. There may be other genetic factors
that contribute to hereditary breast cancer, since not all families with
multiple cases of breast cancer harbor germ-line BRCA1 or BRCA2 mutations. Host
factors (such as lifestyle choices) and other genes may modulate risk of breast
cancer in mutation carriers -
http://www3.interscience.wiley.com/cgi-bin/fulltext/72500613/PDFSTART
-
A
Systematic Review Of Genetic Polymorphisms and Breast Cancer Risk: In
this study the authors have identified 46 published case-control studies that
have examined the effect of common alleles of 18 different genes on breast
cancer risk. Of these, 12 report statistically significant associations, none of
which were reported by more than one study. However, many of the studies were
small: 10 of the 46 had 80% power or greater to detect a rare allele homozygote
relative risk <2.5. We therefore combined the results of individual studies to
obtain more precise estimates of risk -
http://cebp.aacrjournals.org/cgi/content/full/8/10/843
-
Polymorphisms of
glutathione S-transferase genes (GSTM1, GSTP1 and GSTT1) and breast cancer
susceptibility: The glutathione S-transferase (GST) family of enzymes
function in the body to detoxify carcinogenic compounds. Several genes that code
for these enzymes are polymorphic, with particular genotypes previously shown to
confer an increased cancer risk. In this study, we investigated the role of
three GST genes (GSTM1, GSTP1 and GSTT1) in the development of sporadic breast
cancer. Results did not support an involvement of these specific GST gene
polymorphisms, either independently or in combination, in susceptibility to
sporadic breast cancer in the tested Australian Caucasian population -
http://dx.doi.org/10.1016/S0304-3835(00)00361-X
-
Breast cancer risk
associated with genotypic polymorphism of the genes involved in the
estrogen-receptor-signaling pathway: a multigenic study on cancer
susceptibility: The reproductive hormone, estrogen, contributes to
the development of breast cancer by binding to the estrogen receptor (ER) in the
nucleus, triggering cell growth and tumour promotion. In addition to its role in
regulating target genes and signalling pathways involved in cell cycle
progression, the ER-signalling pathway may regulate the expression of
chromatin-remodelling gene, Metastasis-associated 3 (MTA3), or interact with
chromatin-remodelling protein, Metastasis-associated 1 (MTA1). The
epidemiological findings of this study highlight the role of newly identified
novel ER-related pathways in breast cancer development and provide a more
comprehensive picture of the tumorigenic effect of estrogen in breast cancer
development -
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16502042
-
DNA Copy Number Losses at
1p32-pter in Monozygotic Twins Concordant for Breast Cancer:
To find
similarities that may possibly indicate novel mutations, we performed
comparative genomic hybridization (CGH) analysis following degenerate
oligonucleotide primed polymerase chain reaction (PCR) for DNA obtained from
unique material of breast cancer that developed in monozygotic twin-pairs. The
most frequent loss, detected in half of the abnormal cases, was at 1p32-pter -
http://dx.doi.org/doi:10.1016/S0165-4608(98)00274-X
-
High-Resolution Genomic Profiling Reveals Association of Chromosomal Aberrations
on 1q and 16p with Histologic and Genetic Subgroups of Invasive Breast Cancer:
Invasive ductal carcinoma and invasive lobular carcinoma (ILC) represent the
major histologic subtypes of invasive breast cancer. They differ with regard to
presentation, metastatic spread, and epidemiologic features. To elucidate the
genetic basis of these differences, we analyzed copy number imbalances that
differentiate the histologic subtypes. Molecular profiling using bacterial
artificial chromosome arrays identified DNA copy number imbalances on 1q and 16p
as significant classifiers of histologic and molecular subgroups -
http://clincancerres.aacrjournals.org/cgi/content/full/12/2/345
-
Bcl-2 gene
family and related proteins in mammary gland involution and breast cancer:
Understanding the role Bcl-2 family members play in regulating mammary
epithelial cell survival is salient to both normal mammary gland physiology and
the development of new therapeutic approaches to breast cancer. Family members
are characterized as either pro-apoptotic or anti-apoptotic, depending on
cellular context. In addition to its anti-apoptotic effect, Bcl-2 also inhibits
progression through the cell cycle -
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=99353437&dopt=Abstract
-
Genetics of Breast and
Ovarian Cancer - Major Genes Involved: After gender and age, a
positive family history is the strongest known predictive risk factor for breast
cancer. Hereditary breast cancer is characterized by early age at onset (on
average 5-15 years earlier than in sporadic cases), bilaterality, vertical
transmission through both maternal and paternal lines, and familial association
with tumours of other organs, particularly the ovary and prostate gland. The
clinical evidence of an autosomal dominant inherited predisposition to breast
cancer has been supported by segregation analysis. The search for genes
associated with hereditary susceptibility to breast cancer has been facilitated
by the study of large kindreds with multiple affected individuals, and has led
to the identification of several susceptibility genes, including BRCA1, BRCA2,
TP53, and PTEN/MMAC1 -
http://www.cancer.gov/templates/doc.aspx?viewid=6bc9885b-da37-4407-866a-c2c7170fc548&version=HealthProfessional§ionID=88&#Section_79
-
Genetic
Polymorphism and Breast Cancer Risk: Evidence of associations between
genetic polymorphisms and breast cancer risk in women has been obtained from
case-control or cohort (nested case-control) analytic studies, usually with just
a single centre or research group (level of evidence: 3). Results have largely
been inconsistent, and none of the markers has had clinical applications -
http://www.cancer.gov/cancertopics/pdq/genetics/breast-and-ovarian/HealthProfessional/page3
Epidemiology of
the Breast Cancer:
Screening for
Breast Cancer:
-
Screening for Genetic Risk of
Breast Cancer - a comprehensive review:
Approximately 10 to 15 percent of all breast cancers are thought to be familial
and about one third of these cases are due to an inherited mutation in a BRCA1
or BRCA2 breast cancer susceptibility gene. The lifetime incidence of breast
cancer in mutation carriers is above 50 percent, and carriers of BRCA1 mutation
also have a substantially increased risk of ovarian cancer. BRCA1 and 2
mutations are associated with early-onset breast cancer, and some experts call
for aggressive screening of affected persons. A family history remains the best
tool for planning breast cancer surveillance. As experience with BRCA1 and 2
mutations increases, the role of genetic screening may be clarified for both
society at large and the medical community -
http://www.aafp.org/afp/990101ap/99.html
-
Who is screened for breast cancer
by the UK breast screening programme:
http://www.cancerhelp.org.uk/help/default.asp?page=3303
General
Overview:
Genetic Testing:
Hormonal Assays
for Breast Cancer:
Screening Tests
for Breast Cancer:
Mammography:
Ultrasonography:
Breast Biopsy:
Questionnaires:
Document Author: Dr. Fazal Danish
Document Created: 14th March 2006
Document Edits:
|